CN117597135A - Mazdutide的应用 - Google Patents

Mazdutide的应用 Download PDF

Info

Publication number
CN117597135A
CN117597135A CN202280045316.5A CN202280045316A CN117597135A CN 117597135 A CN117597135 A CN 117597135A CN 202280045316 A CN202280045316 A CN 202280045316A CN 117597135 A CN117597135 A CN 117597135A
Authority
CN
China
Prior art keywords
dose
uric acid
weeks
week
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280045316.5A
Other languages
English (en)
Chinese (zh)
Inventor
安培
邓焕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics (Suzhou) Co Ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of CN117597135A publication Critical patent/CN117597135A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280045316.5A 2021-06-25 2022-06-23 Mazdutide的应用 Pending CN117597135A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110711050 2021-06-25
CN2021107110500 2021-06-25
PCT/CN2022/100878 WO2022268174A1 (zh) 2021-06-25 2022-06-23 Mazdutide的应用

Publications (1)

Publication Number Publication Date
CN117597135A true CN117597135A (zh) 2024-02-23

Family

ID=84544128

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280045316.5A Pending CN117597135A (zh) 2021-06-25 2022-06-23 Mazdutide的应用

Country Status (9)

Country Link
US (1) US20240293513A1 (cg-RX-API-DMAC10.html)
EP (1) EP4360641A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524273A (cg-RX-API-DMAC10.html)
KR (1) KR20240027053A (cg-RX-API-DMAC10.html)
CN (1) CN117597135A (cg-RX-API-DMAC10.html)
AU (1) AU2022298841A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224043A1 (cg-RX-API-DMAC10.html)
TW (2) TW202617173A (cg-RX-API-DMAC10.html)
WO (1) WO2022268174A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023281591A1 (en) * 2022-06-01 2025-01-02 Innovent Biologics (Suzhou) Co., Ltd. Treatment method using mazdutide
EP4788362A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
EP4788356A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating adolescent obesity
WO2025098422A1 (zh) * 2023-11-07 2025-05-15 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
AU2023281591A1 (en) * 2022-06-01 2025-01-02 Innovent Biologics (Suzhou) Co., Ltd. Treatment method using mazdutide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAI-SAN THAM等: "A First-in-Human Single Ascending Dose Study of Oxyntomodulin Analog LY3305677 in Healthy Subjects", DIABETES, 1 June 2021 (2021-06-01), pages 1 - 6 *
李悦等: "肥胖与高尿酸血症的相关研究现况", 世界最新医学信息文摘, 31 December 2019 (2019-12-31), pages 128 - 129 *

Also Published As

Publication number Publication date
US20240293513A1 (en) 2024-09-05
JP2024524273A (ja) 2024-07-05
TW202300171A (zh) 2023-01-01
EP4360641A4 (en) 2025-10-22
CA3224043A1 (en) 2022-12-29
EP4360641A1 (en) 2024-05-01
TW202617173A (zh) 2026-05-01
AU2022298841A1 (en) 2024-01-25
WO2022268174A1 (zh) 2022-12-29
KR20240027053A (ko) 2024-02-29

Similar Documents

Publication Publication Date Title
WO2022268174A1 (zh) Mazdutide的应用
Peterson Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
RU2623023C2 (ru) Ликсисенатид и метформин для лечения диабета типа 2
Shestakova et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
EP2324853A1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
US20250296973A1 (en) Treatment method using mazdutide
Garnock-Jones et al. Insulin glulisine: a review of its use in the management of diabetes mellitus
TW202237175A (zh) 治療糖尿病之方法
McFarlane Antidiabetic medications and weight gain: implications for the practicing physician
US20240390464A1 (en) Treatment of Adults With Overweight or Obesity With or Without Weight-Related Comorbidities
CN112057619A (zh) 一种具有降血糖作用的药物组合物
Roy Administration of once-daily canagliflozin to a non-diabetic patient in addition to standard aerobic exercise: a case report
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
HK40110048A (en) Use of mazdutide
TW202140061A (zh) 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
WO2023235724A1 (en) Methods of using a gcg/glp1 co-agonist for therapy
CN108883158A (zh) 用于肾脏病况的利拉鲁肽
HK40118093A (en) Treatment method using mazdutide
CN108883159A (zh) 用于糖尿病性足溃疡的利拉鲁肽
WO2026037397A1 (zh) Glp-1类似物的医药用途
Mikhail Appraisal of Once-Weekly Insulin Icodec
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
JP2021528424A (ja) 対象における食後のグルコースレベルをコントロールする方法および使用
CN113509544A (zh) 一种具有降血糖作用的药物组合物
Edelman Intensive Insulin Therapy in T2DM

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106921

Country of ref document: HK